Michael H. Handler
YOU?
Author Swipe
View article: Multi‐pronged analysis of pediatric low‐grade glioma and ganglioglioma reveals a unique tumor microenvironment associated with <scp>BRAF</scp> alterations
Multi‐pronged analysis of pediatric low‐grade glioma and ganglioglioma reveals a unique tumor microenvironment associated with <span>BRAF</span> alterations Open
Pediatric low‐grade gliomas (pLGG) comprise 35% of all brain tumors. Despite favorable survival, patients experience significant morbidity from disease and treatments. A deeper understanding of pLGG biology is essential to identify novel, …
View article: EPEN-24. 5FU SENSITIVITY IS MEDIATED THROUGH TRISOMY UCK2 EXPRESSION IN 1Q+ PFA EPN
EPEN-24. 5FU SENSITIVITY IS MEDIATED THROUGH TRISOMY UCK2 EXPRESSION IN 1Q+ PFA EPN Open
BACKGROUND Nearly all children with gain of chromosome 1q (1q+) PFA ependymoma (EPN) will die, highlighting the urgent need to develop new treatment strategies for these patients. It has recently been shown that 1q+ creates a p53 mutant-li…
View article: Data from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Data from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma Open
Purpose:There are no effective treatment strategies for children with highest-risk posterior fossa group A ependymoma (PFA). Chromosome 1q gains (1q+) are present in approximately 25% of newly diagnosed PFA tumors, and this number doubles …
View article: Supplementary Figure S4 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Supplementary Figure S4 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma Open
MDM4 gene expression with 5FU treatment
View article: Supplementary Figure S8 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Supplementary Figure S8 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma Open
MAF-811_XC in vivo survival with radiation and chemotherapy.
View article: Supplementary Figure S4 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Supplementary Figure S4 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma Open
MDM4 gene expression with 5FU treatment
View article: Supplementary Figure S2 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Supplementary Figure S2 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma Open
Combination of radiation with 5FU is synergistic in 1q+ PFA cell lines.
View article: Supplementary Figure S3 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Supplementary Figure S3 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma Open
Densitometry for apoptosis proteomic array of 1q+ PFA cell lines treated with 5FU and 5Gy radiation.
View article: Supplementary Figure S2 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Supplementary Figure S2 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma Open
Combination of radiation with 5FU is synergistic in 1q+ PFA cell lines.
View article: Data from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Data from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma Open
Purpose:There are no effective treatment strategies for children with highest-risk posterior fossa group A ependymoma (PFA). Chromosome 1q gains (1q+) are present in approximately 25% of newly diagnosed PFA tumors, and this number doubles …
View article: Supplementary Figure S7 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Supplementary Figure S7 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma Open
Tretinoin (ATRA) identified as an EPN specific target
View article: Supplementary Figure S5 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Supplementary Figure S5 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma Open
MAF-811_XC in vivo survival with radiation and chemotherapy.
View article: Supplementary Figure S1 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Supplementary Figure S1 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma Open
5FU at 75mg/kg in combination with 10Gy radiation is too toxic in vivo
View article: Supplementary Figure S8 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Supplementary Figure S8 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma Open
MAF-811_XC in vivo survival with radiation and chemotherapy.
View article: Supplementary Figure S7 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Supplementary Figure S7 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma Open
Tretinoin (ATRA) identified as an EPN specific target
View article: Supplementary Figure S1 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Supplementary Figure S1 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma Open
5FU at 75mg/kg in combination with 10Gy radiation is too toxic in vivo
View article: Supplementary Figure S3 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Supplementary Figure S3 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma Open
Densitometry for apoptosis proteomic array of 1q+ PFA cell lines treated with 5FU and 5Gy radiation.
View article: Supplementary Figure S6 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Supplementary Figure S6 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma Open
MAF-928 in vivo mice had more metastatic lesions with radiation alone.
View article: Supplementary Figure S5 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Supplementary Figure S5 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma Open
MAF-811_XC in vivo survival with radiation and chemotherapy.
View article: Supplementary Figure S6 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Supplementary Figure S6 from Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma Open
MAF-928 in vivo mice had more metastatic lesions with radiation alone.
View article: Multi-pronged analysis of pediatric low-grade glioma reveals a unique tumor microenvironment associated with BRAF alterations
Multi-pronged analysis of pediatric low-grade glioma reveals a unique tumor microenvironment associated with BRAF alterations Open
Pediatric low-grade gliomas (pLGG) comprise 35% of all brain tumors. Despite favorable survival, patients experience significant morbidity from disease and treatments. A deeper understanding of pLGG biology is essential to identify novel, …
View article: Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma
Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma Open
Purpose: There are no effective treatment strategies for children with highest-risk posterior fossa group A ependymoma (PFA). Chromosome 1q gains (1q+) are present in approximately 25% of newly diagnosed PFA tumors, and this number doubles…
View article: Genetic predictors of neurocognitive outcomes in survivors of pediatric brain tumors
Genetic predictors of neurocognitive outcomes in survivors of pediatric brain tumors Open
Background Neurocognitive deficits are common in pediatric brain tumor survivors. The use of single nucleotide polymorphism (SNP) analysis in DNA repair genes may identify children treated with radiation therapy for brain tumors at increas…
View article: Genetic Predictors of Neurocognitive Outcomes in Survivors of Pediatric Brain Tumors
Genetic Predictors of Neurocognitive Outcomes in Survivors of Pediatric Brain Tumors Open
Purpose : Neurocognitive deficits are common in pediatric brain tumor survivors. The use of single nucleotide polymorphism (SNP) analysis in DNA repair genes may identify children treated with radiation therapy for brain tumors at increase…
View article: Treatment of hydrocephalus following posterior fossa tumor resection: a multicenter collaboration from the Hydrocephalus Clinical Research Network
Treatment of hydrocephalus following posterior fossa tumor resection: a multicenter collaboration from the Hydrocephalus Clinical Research Network Open
View article: Supplementary Figure 5 from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma
Supplementary Figure 5 from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma Open
S3I-201 effects on cell cycle EPN cell line 811 and apoptosis in EPN cell line 723.
View article: Supplementary Figure 5 from Autophagy Inhibition Improves Chemosensitivity in BRAF<sup>V600E</sup> Brain Tumors
Supplementary Figure 5 from Autophagy Inhibition Improves Chemosensitivity in BRAF<sup>V600E</sup> Brain Tumors Open
PDF file 31K, Autophagic flux by flow cytometry in vemurafenib treated cells
View article: Supplementary Figure 4 from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma
Supplementary Figure 4 from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma Open
Concentration of cytokine secretion from flow sorted disaggregated tumor samples.
View article: Data from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma
Data from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma Open
Ependymoma (EPN) in childhood is a brain tumor with substantial mortality. Inflammatory response has been identified as a molecular signature of high-risk Group A EPN. To better understand the biology of this phenotype and aid therapeutic …
View article: Supplementary Figure 6 from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma
Supplementary Figure 6 from Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma Open
IL-6 is the driving cytokine for immune suppressive phenotype observed in 811 CM monocytes.